DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (BPd) vs Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel,1 Randy Davis,2 Nicole M. Lewis,3 Kalpana K. Bakshi,3 Bikramjit Chopra,4 Rocio Montes de Oca,5 Geraldine Ferron-Brady,6 Laurie Eliason,7 Brandon E. Kremer,8 Ira Gupta,3 Frank S. Wu3

1Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada; 2Biostatistics, GlaxoSmithKline, Research Triangle Park, NC, USA; 3Clinical Oncology, GlaxoSmithKline, Upper Providence, PA, USA; 4Pharmacovigilance, GlaxoSmithKline, London, UK; 5Experimental Medicine Unit Oncology, GlaxoSmithKline, Philadelphia, PA, USA; 6Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Upper Providence, PA, USA; 7Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA; 8Clinical Development, GlaxoSmithKline, Upper Providence, PA, USA

Poster No. 2302 | Presented at the 62nd American Society of Hematology Annual Meeting and Exposition (Virtual Format) | December 5–8, 2020
**Background**

**Aims:** To evaluate the efficacy and safety of belantamab mafodotin (belamaf, BLENREP) in combination with pomalidomide and dexamethasone (Pd) compared with Pd plus bortezomib (PVd) in patients with RRMM

**Unmet need**

Patients with MM relapsed/refractory to immunomodulatory drugs and a PI have a poor prognosis (median OS of 15.2 months); for those who are also refractory to daratumumab, OS is further reduced (median OS 8.6 months). Novel, well-tolerated treatments that induce lasting responses are warranted.

**Combination regimens**

- Pd is a standard of care treatment for patients with RRMM; however the median PFS achieved is only 4.2 months so it is generally used in a triplet regimen
- PVd is an approved triplet regimen that has demonstrated improved anti-myeloma activity versus doublet regimens, such as Vd; there is a need for other triplet regimens containing immunomodulatory and/or novel agents
- Pre-clinical data in animal models suggest significant added benefit (efficacy and survival) of belamaf combined with Pd over single agents
- Preliminary data from an ongoing Phase I/II study (NCT03715478) evaluating BPD have shown manageable safety and promising clinical activity in patients with RRMM

**Belamaf**

- First-in-class BCMA–targeting ADC with a multimodal mechanism of action approved in the US and the EU
- In the Phase II DREAMM-2 study, single-agent belamaf demonstrated deep and durable responses with a manageable safety profile in heavily pre-treated patients with RRMM
- At 13 months of follow-up, responses with belamaf (2.5 mg/kg; IV Q3W) were sustained; ORR was 32%; estimated median DoR and OS were 11.0 and 13.7 months, respectively. At the data cut-off, 10% (10/97) of patients remained on study treatment

**Belamaf Mechanisms of Action**

1. ADC mechanism
2. ADCC/ADCP mechanism
3. Potential immunogenic cell death

---

**Notes:**

- Administered over 0.5–1hr as an outpatient
- Data cut: January 2020
- Image adapted from Richardson P, et al. Presented at the 61st Annual Meeting of the American Society of Hematology, December 7–10, 2019, Orlando, FL. Poster 1857
- ADC, antibody-drug conjugate; ADCC/ADCP, antibody-dependent cellular cytotoxicity/phagocytosis; BCMA, B-cell maturation antigen; belamaf, belantamab mafodotin; BPd, belamaf plus pomalidomide and dexamethasone; DoR, duration of response; IV, intravenously; OS, overall survival; ORR, overall response; Q3W, every 3 weeks; Pd, pomalidomide and dexamethasone; PVd, pomalidomide, bortezomib, and dexamethasone; Vd, bortezomib and dexamethasone
- Kumar SK, et al. Leukemia 2017;31:2443
- Dimopoulus M, et al. Leukemia 2020; DOI:10.1038/s41375-020-01021-3
- Holstein S, et al. Drugs 2017;77:505
- Trudel S, et al. EHA 2019; Poster 294851
- Lonial S, et al. ASCO 2020 Poster 438
Methods

The DREAMM-8 trial (NCT04484623) is a randomized, open-label, multi-center, Phase III study evaluating the efficacy and safety of BPd (Arm A) compared with PVd (Arm B) in patients with RRMM. This is a registrational study.

Study Design

Arm A: BPd (n=225)
- 28-day cycles
  - Belanaf 2.5/1.9 mg/kg (IV)†
  - Pomalidomide 4 mg (PO)§
  - Dexamethasone 40 mg (PO)‡
- Week 1
- Week 2
- Week 3
- Week 4

Arm B: PVd (n=225)
- 21-day cycles
  - Pomalidomide 4 mg (PO)
  - Bortezomib 1.3 mg/m² (SC)
  - Dexamethasone 20 mg (PO)‡
- Week 1
- Week 2
- Week 3

Screening/ baseline

Stratification* (LOT 1 vs 2/3 vs ≥4; prior bortezomib exposure; ISS I vs II/III)

Randomization 1:1

Screening (~560 patients) ≥1L RRMM

Follow-up period

PFS
- Disease assessments Q4W until disease progression, death, or start of new anti-cancer therapy

MRD
- Assessments every 6 months from ≥VGPR until disease progression or CR

OS
- Disease assessments every 3 months until death, withdrawal of consent, loss to follow-up or end of study

*No more than 50% of patients with ≥2 prior lines of treatment and no more than 15% of patients with ≥4 prior lines; †Belanaf: 2.5 mg/kg in Cycle 1 and 1.9 mg/kg in Cycle 2+; §Dexamethasone: dose may be reduced by half in patients >75 years of age or those with comorbidities or intolerant to dexamethasone; ‡Bortezomib: Cycles 9+ on Days 1 and 8; ¶Dexamethasone: Cycles 9+ on Days 1, 2, 8, and 9.

1L, first line; ADA, anti-drug antibodies; belanaf, belantamab mafodotin; BPd, belanaf plus pomalidomide and dexamethasone; Pd, pomalidomide and dexamethasone; Q4W, every 4 weeks; RRMM, relapsed/refractory multiple myeloma; SC, subcutaneous.
## Objectives and Endpoints

### Primary Objective
**Objective**
Compare the efficacy of BPd vs. PVd

**Endpoint**
PFS

### Key Secondary Objective
**Objective**
Further assess clinical activity of BPd vs. PVd

**Endpoints**
- MRD negativity rate*

### Secondary Objective
- Further assess the efficacy of BPd
- Evaluate the safety and tolerability of BPd
- Describe exposure of belamaf when administered with Pd
- Evaluate the PK of BPd
- Assess ADAs against belamaf
- Evaluate the safety and tolerability of belamaf based on self-reported symptomatic AEs when administered with Pd
- Evaluate and compare changes in symptoms and HRQoL

**Endpoints**
- ORR, CRR, ≥VGPR rate, DoR, TTBR, TTR, TTP, OS, PFS2
- AEs and changes in laboratory parameters, ocular findings
- Plasma concentrations, total mAb, and cys-mcMMAF
- Derived PK parameter values
- Incidence and titers of ADAs
- Changes from baseline in symptoms and related impacts, as measured by PRO-CTCAE
- Change from baseline in HRQoL, as measured by EORTC QLQ-C30 and EORTC IL52

*Defined as percentage of patients who are MRD negative by next generation sequencing.

AD, anti-drug antibody; AE, adverse event; belamaf, belantamab mafodotin; BPd, belamaf plus pomalidomide and dexamethasone; CRR, complete response rate; cys-mcMMAF, cysteine-monoethylmonocrotyl monomethyl auristatin F; DoR, duration of response; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; HRQoL, health-related quality of life; mAb, monoclonal antibodies; MM, multiple myeloma; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; Pd, pomalidomide and dexamethasone; PFS, progression-free survival; PVd, pomalidomide plus bortezomib and dexamethasone; TTBR, time to best response; TTP, time to progression; TTR, time to response; VGPR, very good partial response.
Patient Population

**Key inclusion criteria**

- Age ≥18 years
- Confirmed MM (IMWG criteria)†
- Measurable disease (according to serum and/or urine M-protein and/or serum free light chain levels)
- ECOG Performance Status 0–2
- ≥1 prior line of therapy,* including a lenalidomide-containing regimen†
- History of autologous SCT (if >100 days prior to initiation of study treatment and no active infections)
- All prior treatment-related toxicities Grade ≤1 at the time of enrolment‡
- Acceptable organ system function
- Informed consent

**Key exclusion criteria**

- Active plasma cell leukemia, symptomatic amyloidosis or active POEMS syndrome
- Prior allogeneic SCT
- Prior exposure to anti-BCMA therapy
- Prior treatment with or intolerance to pomalidomide, or intolerance/refractory to bortezomib
- Prior treatment with other mAbs within 30 days, investigational agent or systemic anti-myeloma therapy within 14 days or 5 half-lives (whichever is shorter), plasmapheresis within 7 days of first dose of study drug
- Evidence of cardiovascular risk
- Presence of active renal condition, mucosal or internal bleeding, cirrhosis or current unstable liver or biliary disease, infection or HIV
- Ongoing Grade ≥2 peripheral neuropathy or neuropathic pain
- Current corneal epithelial disease (except mild punctate keratopathy)

---

*Patients must have documented disease progression during or after the most recent therapy; †Lenalidomide must have been administered for ≥2 consecutive cycles; ‡Except alopecia.

BCMA, B-cell maturation antigen; ECOG, Eastern Cooperative Oncology Group Performance Status; HIV, human immunodeficiency virus; IMWG, The International Myeloma Working Group; mAb, monoclonal antibody; MM, multiple myeloma; POEMS, polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, and skin changes; SCT, stem cell transplantation.

Current status

The DREAMM-8 study started in October 2020 and aims to enroll 450 patients with RRMM worldwide.

Estimated Study Dates

- **Primary Completion** ~ April 2022
- **Study End** ~ January 2027

Currently participating countries

- Australia
- Greece
- Spain
- United States of America

More countries will be added soon.

The BCMA-targeting MoA of belamaf supports combination with other therapies, including Pd, offering the potential for a manageable safety profile with enhanced efficacy.

Phase I data on BPd are presented as an oral presentation 725 at this meeting. Belamaf is being evaluated in other combination strategies in various MM settings (posters 1419, 2302, 3247). Further analyses of the pivotal DREAMM-2 study of single-agent belamaf are presented at this meeting (posters 1417, 2278, 3221, 3224, 3248).

BCMA, B-cell maturation antigen; belamaf, belantamab mafodotin; BPd, belamaf plus pomalidomide and dexamethasone; MM, multiple myeloma; MoA, mode of action; Pd, pomalidomide and dexamethasone; RRMM, relapsed/refractory multiple myeloma.

Disclosures and Acknowledgments

The authors would like to acknowledge Katarina Luptakova and Joanna Opalinska for their contributions to developing the study design.

This study was funded by GlaxoSmithKline (GSK; 207499). Drug linker technology licensed from Seagen Inc.; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.

Editorial assistance was provided by Joanna Nikitorowicz-Buniak of Fishawack Indicia Ltd. part of Fishawack Health and funded by GSK.

ST has received consultancy fees from Amgen, Celgene, and GSK, research funding from Amgen, Celgene, Genentech, GSK, and Janssen, and honoraria from Amgen, Celgene, Janssen, Karyopharm, Sanofi, and Takeda. RD, NML, KKB, BC, RM, GF-B, LE, BEK, IG, and FSW are employees of and hold stocks and shares in GSK.

Presenting author contact: suzanne.trudel@uhn.on.ca

Please find the online version of this poster by scanning the QR (Quick Response) code or via http://tago.ca/ash9. Copies of this poster obtained through QR and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.